Hematological MalignancyHALTAging-1NCT07292272
Halt Aging in Survivors of Blood Cancers
A study testing Behavioral Coaching Intervention and Virtual Exercise Platform in people with Hematological Malignancy and Leukemia, run by University of Nebraska at 1 site in United States.
Trial summary
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Hematological Malignancy, Leukemia, Lymphoid Leukemia
- What is being tested?
- Behavioral Coaching Intervention and Virtual Exercise Platform
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Apr 2026to 25 Mar 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥50 years
- A history of hematological malignancy
- Participants must be able to and willingly give informed consent
Who cannot join
- Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
- Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
- Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
- Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 <10 ml/kg/min).
- Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
- Self-reported pregnancy or the possibility of pregnancy.
- Participants who do not plan to follow up at the participating center.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, 68008
IIT Office IIT Office, 402-559-4596, IITOffice@unmc.edu
Vijaya Bhatt, MBBS
About this study
Official title: Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.
- Conditions
- Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia
- Being tested
- Behavioral Coaching Intervention, Virtual Exercise Platform
- Keywords
- Hodgkin Lymphoma, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition, Epigenetic clock, Biological aging, Quality of life, Blood cancer survivors
- Medical subject headings
- Hematologic Neoplasms, Leukemia, Leukemia, Lymphoid, Multiple Myeloma, Leukemia, Myeloid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Hodgkin Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral Coaching InterventionBehavioural
Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence
Virtual Exercise PlatformBehavioural
Access to a virtual exercise platform that provides exercise classes and educational sessions for older survivors of blood cancer
| Study group | Role | What they receive |
|---|---|---|
| Intervention Arm: Exercise + Behavioral Coaching | Experimental | Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence Receives: Behavioral: Behavioral Coaching Intervention; Behavioral: Virtual Exercise Platform |
| Enhanced Usual Care-Virtual Gym | Active comparator | Participants will receive access to a virtual exercise platform, and educational sessions but will not receive behavioral coaching Receives: Behavioral: Virtual Exercise Platform |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.
Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries.
Measured: 6 Months from start of program
Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.
Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries to assess sustainability of adherence.
Measured: 12 Months from start of program.
Secondary outcomes (1)
Physical Function (6- Minute Walk Test Distance)
Distance covered during the 6-minute walk test (6MWT) to assess physical function.
Measured: 6 months from randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start9 Apr 2026
- Primary completion25 Mar 2032 (estimated)
- Study completion25 Mar 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematological MalignancyStudies of the same condition, open and under way.
- More trials run by University of NebraskaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vijaya Raj Bhatt, MBBS,MS, Principal investigator, University of Nebraska
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07292272
- Sponsor's protocol ID
- 606-25-FB
- Acronym
- HALTAging-1
- Status last verified
- Dec 2025
- First submitted
- 5 Dec 2025
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
- ClinicalTrials.gov ID
- NCT07292272
- Acronym / sponsor ID
- HALTAging-1 / 606-25-FB
- Conditions
- Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia
- Keywords
- Hodgkin Lymphoma, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- University of NebraskaUniversity, hospital or other
- Study start
- 9 Apr 2026 (actual)
- Primary completion
- 25 Mar 2032 (estimated)
- Study completion
- 25 Mar 2033 (estimated)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Arm: Exercise + Behavioral Coaching | Experimental | Behavioral: Behavioral Coaching Intervention, Behavioral: Virtual Exercise PlatformIntervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence |
| Enhanced Usual Care-Virtual Gym | Active comparator | Behavioral: Virtual Exercise PlatformParticipants will receive access to a virtual exercise platform, and educational sessions but will not receive behavioral coaching |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥50 years
- A history of hematological malignancy
- Participants must be able to and willingly give informed consent
Key exclusion criteria (7 listed)
- Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
- Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
- Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
- Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 <10 ml/kg/min).
- Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioral Coaching InterventionIntervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence | Behavioural | Intervention Arm: Exercise + Behavioral Coaching |
| Virtual Exercise PlatformAccess to a virtual exercise platform that provides exercise classes and educational sessions for older survivors of blood cancer | Behavioural | Enhanced Usual Care-Virtual Gym, Intervention Arm: Exercise + Behavioral Coaching |
Primary outcome
Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.
Time frame: 6 Months from start of program
Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries.
Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.
Time frame: 12 Months from start of program.
Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries to assess sustainability of adherence.
1 secondary outcome
Physical Function (6- Minute Walk Test Distance)
Time frame: 6 months from randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Hematological Malignancy
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
RecruitingEarly Phase 1
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Hematologic Malignancy
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vijaya Raj Bhatt, MBBS,MS principal investigator
University of Nebraska
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Behavioral Coaching Intervention and Virtual Exercise Platform in people with Hematological Malignancy and Leukemia, run by University of Nebraska at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Taylor Johnson (402-559-4596, taylora.johnson@unmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants who adhered to the exercise regimen at 6-months post enrollment. (time frame: 6 Months from start of program). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.